Fig. 7

Strategy for GPX4 Inhibition. A Traditional GPX4 inhibitors, such as RSL3, lead to the loss of GPX4 activity. As GPX4 is widely expressed in both immune and cancer cells, they induce non-selective ferroptosis. B N6F11 can bind to TRIM25, subsequently triggering TRIM25-dependent GPX4 degradation to induce ferroptosis. Given that TRIM25 is mainly expressed in cancer cells, the use of N6F11 does not induce ferroptosis in non-cancer cells